Tomoko Akaike
Overview
Explore the profile of Tomoko Akaike including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akaike T, Jabbour A, Goff P, Park S, Bhatia S, Nghiem P
J Immunother Cancer
. 2024 Jul;
12(7.
PMID: 39053946
Merkel cell carcinoma (MCC) incidence has risen to approximately 3,000 cases annually in the USA. Although anti-programmed cell death (ligand) 1 (PD-(L)1) agents are now the first-line treatment for advanced...
2.
Akaike T, Thakuria M, Silk A, Hippe D, Park S, So N, et al.
J Clin Oncol
. 2024 Jul;
42(26):3151-3161.
PMID: 39052958
Purpose: Merkel cell carcinoma (MCC) is an aggressive skin cancer with a 40% recurrence rate, lacking effective prognostic biomarkers and surveillance methods. This prospective, multicenter, observational study aimed to evaluate...
3.
Singh N, McClure E, Akaike T, Park S, Huynh E, Goff P, et al.
Curr Treat Options Oncol
. 2023 Jul;
24(9):1231-1258.
PMID: 37403007
Merkel cell carcinoma (MCC) has a high risk of recurrence and requires unique treatment relative to other skin cancers. The patient population is generally older, with comorbidities. Multidisciplinary and personalized...
4.
Akaike T, Cahill K, Akaike G, Huynh E, Hippe D, Shinohara M, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497395
Merkel cell carcinoma (MCC), an aggressive neuroendocrine skin cancer, has a high rate (20%) of distant metastasis. Within a prospective registry of 582 patients with metastatic MCC (mMCC) diagnosed between...
5.
Akaike T, Nghiem P
J Dermatol Sci
. 2021 Nov;
105(1):2-10.
PMID: 34836718
Merkel cell carcinoma (MCC) is a primary neuroendocrine skin cancer that recurs in ~40% of cases. Merkel cell polyomavirus (MCPyV) and ultraviolet (UV)-induced mutations are two major causative factors of...
6.
Breneman A, Akaike T, Paulson K, Breneman D, Nghiem P
JAAD Case Rep
. 2021 Sep;
16:58-61.
PMID: 34522748
No abstract available.
7.
Nghiem P, Bhatia S, Lipson E, Sharfman W, Kudchadkar R, Brohl A, et al.
J Immunother Cancer
. 2021 Apr;
9(4).
PMID: 33879601
Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with...
8.
Park S, Doolittle-Amieva C, Moshiri Y, Akaike T, Parvathaneni U, Bhatia S, et al.
Future Oncol
. 2021 Jan;
17(11):1363-1377.
PMID: 33511866
Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with a high risk of local recurrence and distant metastasis. Optimal care of this potentially life-threatening cancer is critical but...
9.
Barrios D, Do M, Phillips G, Postow M, Akaike T, Nghiem P, et al.
J Am Acad Dermatol
. 2020 May;
83(5):1239-1253.
PMID: 32461079
As the incidence of cutaneous malignancies continues to rise and their treatment with immunotherapy expands, dermatologists and their patients are more likely to encounter immune checkpoint inhibitors. While the blockade...
10.
Akaike G, Akaike T, Fadl S, Lachance K, Nghiem P, Behnia F
Radiographics
. 2019 Nov;
39(7):2069-2084.
PMID: 31697628
Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor with a higher mortality rate than melanoma. Approximately 40% of MCC patients have nodal or distant metastasis at...